Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simtuzumab + gemcitabine
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Simtuzumab + gemcitabine is an experimental combination therapy evaluated for metastatic pancreatic adenocarcinoma. Simtuzumab is a humanized IgG4 monoclonal antibody developed to inhibit lysyl oxidase-like 2 (LOXL2), an extracellular matrix-remodeling enzyme implicated in tumor stroma maintenance and fibrotic disease. By inhibiting LOXL2, simtuzumab aims to disrupt the pathological tumor microenvironment and impede cancer progression. Gemcitabine is a cytotoxic antimetabolite chemotherapy that inhibits DNA synthesis in rapidly dividing cells. In a randomized phase II trial, the addition of simtuzumab to gemcitabine did not improve progression-free survival, overall survival, or objective response rate compared to gemcitabine plus placebo, though the combination was well-tolerated with a safety profile similar to placebo plus gemcitabine[1][6][4].
- Other names
- simtuzumab + gemcitabinesimtuzumabgemcitabine
02
Targets
LOXL2 (Lysyl oxidase-like 2 protein)
Beyond the preview
Go deeper on simtuzumab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simtuzumab + gemcitabine.